MoonLake Immunotherapeutics Files Biologics License Application To FDA For Nanobody Sonelokimab To Treat Hidradenitis Suppurativa

MoonLake Immunotherapeutics has submitted a Biologics License Application (BLA) to the FDA for its nanobody sonelokimab, aimed at treating hidradenitis suppurativa. This application marks a significant step in the company's efforts to bring this treatment to market. The stock ticker for MoonLake Immunotherapeutics is MLTX.